In a randomized, open-label, crossover trial, 37 patients with type 2 diabetes without kidney or coronary disease, received ramipril (2.5 mg/day), telmisartan (40 mg/day) or their combination during three months; a significant decrease in CRP levels were observed in all intra- but no inter-groups comparisons18. The gene discussed is CRP; the disease is type 2 diabetes mellitus.